Original French opinion adopted by the Transparency Committee

The legally binding text is the original French opinion version

SUMMARY

choriogonadotropin alfa

OVITRELLE 250 µg/0.5 ml

solution for injection in pre-filled syringe

Inclusion on list: First listing

Range supplement

Adopted by the Transparency Committee on 12 February 2025

Summary of opinion

Favourable opinion for reimbursement in the treatment of:

- adult women undergoing superovulation prior to assisted reproductive technologies (ART) such as in vitro fertilisation (IVF),
- anovulatory or oligo-ovulatory adult women.

No clinical added value of the new pre-filled syringe form compared to the forms already available.

Transparency Committee's Conclusions

Clinical Benefit

- ➔ Infertility significantly impairs the quality of life of couples.
- ➔ This is a curative medicinal product.
- ➔ The efficacy/adverse effects ratio is high.
- ➔ This is a first-line treatment in view of the therapies available.

➔ Public health benefit

This proprietary medicinal product is unlikely to have an additional impact on public health.

This document and its bibliographic reference are available to download at www.has-sante.fr

This opinion is published subject to intellectual property rights

Haute Autorité de Santé – Communication and Information Department

5 avenue du Stade de France – 93218 SAINT-DENIS LA PLAINE CEDEX – France. Tel.: +33 (0)1 55 93 70 00

© Haute Autorité de santé – February 2025

The Committee considers that the clinical benefit of OVITRELLE (choriogonadotropin alfa) is substantial in the MA indication.

The Committee issues a favourable opinion for inclusion in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the indication and at the MA dosages.

→ Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 100%

Clinical Added Value

This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed.